Produção Nacional
Revisado por pares
N -acetylcysteine for therapy-resistant tobacco use disorder: a pilot study
2015; Taylor & Francis; Volume: 20; Issue: 5 Linguagem: Inglês
10.1179/1351000215y.0000000004
ISSN1743-2928
AutoresEduardo Seixas Prado, Michaël Maes, Luiz Gustavo Piccoli, Marcela M. Baracat, Décio Sabattini Barbosa, Olavo Franco, Seetal Dodd, Michael Berk, Sandra Odebrecht Vargas Nunes,
Tópico(s)Cannabis and Cannabinoid Research
ResumoIntroductionN-Acetylcysteine (NAC) may have efficacy in treating tobacco use disorder (TUD) by reducing craving and smoking reward. This study examines whether treatment with NAC may have a clinical efficacy in the treatment of TUD.MethodsA 12-week double blind randomized controlled trial was conducted to compare the clinical efficacy of NAC 3 g/day versus placebo. We recruited 34 outpatients with therapy resistant TUD concurrently treated with smoking-focused group behavioral therapy. Participants had assessments of daily cigarette use (primary outcome), exhaled carbon monoxide (COEXH) (secondary outcome), and quit rates as defined by COEXH<6 ppm. Depression was measured with the Hamilton Depression Rating Scale (HDRS). Data were analyzed using conventional and modified intention-to-treat endpoint analyses.ResultsNAC treatment significantly reduced the daily number of cigarettes used (Δ mean±SD = −10.9 ± 7.9 in the NAC-treated versus −3.2 ± 6.1 in the placebo group) and COEXH (Δ mean± SD = −10.4 ± 8.6 ppm in the NAC-treated versus −1.5 ± 4.5 ppm in the placebo group); 47.1% of those treated with NAC versus 21.4% of placebo-treated patients were able to quit smoking as defined by COEXH<6 ppm. NAC treatment significantly reduced the HDRS score in patients with tobacco use disorder.ConclusionsThese data show that treatment with NAC may have a clinical efficacy in TUD. NAC combined with appropriate psychotherapy appears to be an efficient treatment option for TUD.
Referência(s)